Depomed To Present At Piper Jaffray 2013 Healthcare Conference PR Newswire NEWARK, Calif., Dec. 2, 2013 NEWARK, Calif., Dec. 2, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Piper Jaffray 25^th Annual Healthcare Conference at The New York Palace Hotel in New York City. The presentation at the Piper conference is scheduled for 12:10 pm EST (9:10 am PST) on Tuesday, December 3, 2013. The presentation will be webcast, and the webcast can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcast will be archived for 30 days on the company's website. About Depomed Depomed, Inc. is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia. Zipsor® (diclofenac potassium) Liquid Filled Capsules is a non-steroidal anti-inflammatory drug indicated for relief of mild to moderate acute pain in adults. Lazanda® (fentanyl) Nasal Spray is an intranasal fentanyl drug used to manage breakthrough pain in adults (18 years of age or older) who are already routinely taking other opioid pain medicines around-the-clock for cancer pain. Gralise and other products and product candidates are formulated with Depomed's proven, proprietary Acuform® drug delivery technology. Additional information about Depomed may be found at www.depomed.com. CONTACT: August J. Moretti Depomed, Inc. 650-462-5900 email@example.com SOURCE Depomed, Inc. Website: http://www.depomed.com
Depomed To Present At Piper Jaffray 2013 Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.